Konstantin Chegaev

List of Publications by Year in Descending Order

56 papers	1,037 citations	20 h-index	30 g-index
60 ext. papers	1,186 ext. citations	5.3 avg, IF	3.62 L-index

#	Paper	IF	Citations
56	Sdox, a HS releasing anthracycline, with a safer profile than doxorubicin toward vasculature.. *Vascular Pharmacology*, **2022**, 143, 106969	5.9	1
55	A Comprehensive Evaluation of Sdox, a Promising HS-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors.. *Frontiers in Pharmacology*, **2022**, 13, 831791	5.6	0
54	NO release regulated by doxorubicin as the green light-harvesting antenna. *Chemical Communications*, **2020**, 56, 6332-6335	5.8	2
53	In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin. *European Journal of Pharmacology*, **2020**, 880, 173164	5.3	3
52	MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118824	4.9	5
51	Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug. *Molecular Pharmaceutics*, **2019**, 16, 4181-4189	5.6	5
50	Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. *Cancer Letters*, **2019**, 456, 29-39	9.9	26
49	In Vitro Assessment of NitDox Toxicity Toward Vasculature **2019**, 319-320		
48	Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. *Cellular and Molecular Life Sciences*, **2019**, 76, 609-625	10.3	32
47	New tetrahydroisoquinoline-based P-glycoprotein modulators: decoration of the biphenyl core gives selective ligands. *MedChemComm*, **2018**, 9, 862-869	5	9
46	New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations. *Investigational New Drugs*, **2018**, 36, 985-998	4.3	19
45	Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells. *Frontiers in Pharmacology*, **2018**, 9, 580	5.6	16
44	New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro. *Molecules*, **2018**, 23,	4.8	9
43	Aceclofenac-Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological Evaluations. *Molecular Pharmaceutics*, **2018**, 15, 3101-3110	5.6	7
42	Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors. *European Journal of Medicinal Chemistry*, **2018**, 144, 612-625	6.8	13
41	Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. *Journal of Controlled Release*, **2018**, 270, 37-52	11.7	47
40	Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis. *Molecular Pharmaceutics*, **2018**, 15, 21-30	5.6	8

39	Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation. *European Journal of Medicinal Chemistry*, **2018**, 154, 341-353	6.8	7
38	Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance. *ACS Medicinal Chemistry Letters*, **2017**, 8, 361-365	4.3	35
37	Solid Lipid Nanoparticles Loaded with Antitumor Lipophilic Prodrugs Aimed to Glioblastoma Treatment: Preliminary Studies on Cultured Cells. *Journal of Nanoscience and Nanotechnology*, **2017**, 17, 3606-3614	1.3	5
36	New furoxan derivatives for the treatment of ocular hypertension. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 479-483	2.9	5
35	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity. *Journal of Medicinal Chemistry*, **2017**, 60, 8647-8660	8.3	29
34	-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension. *ACS Medicinal Chemistry Letters*, **2017**, 8, 1054-1059	4.3	3
33	Direct introduction of cyano group on furoxan ring. *Mendeleev Communications*, **2017**, 27, 565-566	1.9	4
32	Synthesis and Biological Evaluation of N(2) -Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors. *ChemMedChem*, **2016**, 11, 1705-8	3.7	5
31	Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4∀(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein. *Journal of Medicinal Chemistry*, **2016**, 59, 6729-38	8.3	17
30	Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 967-75	3.4	21
29	Solid lipid nanoparticles carrying lipophilic derivatives of doxorubicin: preparation, characterization, and in vitro cytotoxicity studies. *Journal of Microencapsulation*, **2016**, 33, 381-90	3.4	14
28	H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. *Journal of Medicinal Chemistry*, **2016**, 59, 4881-9	8.3	35
27	Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis. *European Journal of Medicinal Chemistry*, **2016**, 123, 523-531	6.8	48
26	A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion. *Oxidative Medicine and Cellular Longevity*, **2015**, 2015, 804659	6.7	18
25	NO-donor thiacarbocyanines as multifunctional agents for Alzheimer∀ disease. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 4688-4698	3.4	16
24	Furazan and furoxan sulfonamides are strong □arbonic anhydrase inhibitors and potential antiglaucoma agents. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 3913-21	3.4	25
23	Leishmanicidal activities of novel synthetic furoxan and benzofuroxan derivatives. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 4837-47	5.9	32
22	Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells. *Molecular Pharmaceutics*, **2014**, 11, 3068-79	5.6	27

21	Doxorubicin-antioxidant co-drugs. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5307-10	2.9	19
20	Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. *Molecular Pharmaceutics*, **2013**, 10, 161-74	5.6	52
19	Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 841-50	3.4	5
18	New nitric oxide or hydrogen sulfide releasing aspirins. *Journal of Medicinal Chemistry*, **2011**, 54, 5478-84	8.3	28
17	Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity. *ACS Medicinal Chemistry Letters*, **2011**, 2, 494-7	4.3	58
16	Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein. *Journal of Medicinal Chemistry*, **2010**, 53, 5467-75	8.3	49
15	Effects of nitric oxide donor antioxidants containing the phenol vitamin E substructure and a furoxan moiety on ischemia/reperfusion injury. *Arzneimittelforschung*, **2009**, 59, 111-6		1
14	Unsymmetrically substituted furoxans. Part 19. Methyl and phenylfuroxansulfonic acids and related sulfonamides. *Journal of Heterocyclic Chemistry*, **2009**, 46, 866-872	1.9	10
13	Edaravone derivatives containing NO-donor functions. *Journal of Medicinal Chemistry*, **2009**, 52, 574-8	8.3	31
12	(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins. *Journal of Medicinal Chemistry*, **2009**, 52, 5058-68	8.3	30
11	Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile. *Journal of Medicinal Chemistry*, **2009**, 52, 4020-5	8.3	4
10	Multitarget drugs: Focus on the NO-donor hybrid drugs. *Pure and Applied Chemistry*, **2008**, 80, 1693-1701	2.1	17
9	Novel antioxidant agents deriving from molecular combination of Vitamin C and NO-donor moieties. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 5199-206	3.4	15
8	NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. *Journal of Medicinal Chemistry*, **2007**, 50, 1449-57	8.3	52
7	Amphiphilic NO-donor antioxidants. *ChemMedChem*, **2007**, 2, 234-40	3.7	2
6	NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization. *Journal of Pineal Research*, **2007**, 42, 371-85	10.4	12
5	Synthesis, chiral HPLC resolution and configuration assignment of 1-phenylglyceryl trinitrate stereomers. *Chirality*, **2006**, 18, 430-6	2.1	6
4	NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties. *Journal of Medicinal Chemistry*, **2006**, 49, 2886-97	8.3	43

3	Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5971-4	2.9	23
2	Synthesis of 2-monofunctionalized 2,4,6,8-tetraazabicyclo[3.3.0]octane-3,7-diones. *Russian Chemical Bulletin*, **2003**, 52, 192-197	1.7	14
1	New functional glycoluril derivatives. *Mendeleev Communications*, **2001**, 11, 32-33	1.9	16